This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Cancer immunotherapy is aimed at activating the patient�s own immune system via the administration of a therapeutic
vaccine. With the development of modern sophisticated engineering technology, it is possible to accelerate the development
of novel and safe cancer vaccines. The challenge in cancer vaccine development is to find the best combination of antigen,
adjuvant and delivery system to produce a strong and long-lasting immune response. Regarding the design of therapeutic cancer
vaccine, seeking a new vaccines vehicle is very important to improving vaccines. Bacillus Calmette-Gu�rin (BCG) is used widely
in human vaccines. It can potentially offer unique advantages for developing a safe and effective multi-vaccine vehicle. BCG is a
new vaccines vehicle. Recent studies have confirmed that rBCG vaccines are indeed functional stable, the live rBCG vaccines are
as safe as the parental BCG strain. Due to these properties, the development of tumor-associated antigen-secreting recombinant
BCG (rBCG) vaccines for cancer immunotherapy has gained great momentum in recent years. Compared to conventional
protein vaccines and viral vectors, the rBCG vaccines for cancer immunotherapy has potential advantages. Several promising
rBCG vaccines secreting tumor-associated antigen have been shown to induce antigen-specific antitumor immune responses
in pre-clinical studies. These results suggest that these rBCG strains coexpressing tumor-associated antigen and cytokines are
promising candidates as cancer vaccines, and thus deserve further investigation. This strategy has the main advantage that can
elicit long-lasting immunological memory that can protect against minimal residual disease and tumor recurrence. Although
the detailed mechanisms for this antitumor effect following rBCG vaccines immunization remains to be illustrated, we believe
that this strategy will provide impetus for future research into the development of better and safer rBCG vaccines against cancer.
Shifang Yuan completed his M.D in 1987 and Ph.D in 2002 from Fourth Military Medical University. He is currently the Director, Professor and Chief surgeon of Department of Vascular and Endocrine Surgery, Xijing Hospital, Fourth Military Medical University. As an visiting professor, he used to worked in Royal Victoria Hospitals, McGill University for one year. He is the member of China Medical Association. He is a specialist of Shaanxi Province anticancer association, China. He has obtained two research grants from the National Natural Science Foundation of China (No. 81072180, No30571802). He has published more than 50 papers in reputed journals and serving as an editorial board member of repute.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals